Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00956280

Enrollment

100

Registered

2009-08-11

Start date

2009-09-30

Completion date

2010-04-30

Last updated

2010-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Keywords

The frequency and type of KRAS mutation in a sample of the Brazilian population with advanced NSCLC, KRAS mutation in population with advanced NSCLC

Brief summary

The purpose of this study is to characterize the demographic and clinical aspects, and describe the frequency and type of KRAS mutation in a Brazilian population sample with advanced non-small cell lung cancer (NSCLC).

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histological or cytological confirmation of locally advanced or metastatic Non Small Cell Lung Cancer (IIIB-IV) * Tumour sample (block of slides) available for KRAS analysis

Exclusion criteria

* Confirmation of locally advanced or metastatic NSCLC (IIIB-IV) exclusively by cytology, with no tumour sample access. * Previous treatment using a MEK inhibitor or any other regimen containing docetaxel (previous treatment with paclitaxel is accepted)

Design outcomes

Primary

Measure	Time frame
To analyze the frequency and type of KRAS mutation in a sample of the Brazilian population with advanced NSCLC.	March 31, 2010

Countries

Brazil

Outcome results